A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Conditions:   Ovarian Cancer;   Platinum-resistant Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
Interventions:   Drug: ZN-c3;   Drug: Niraparib
Sponsor:   K-Group Beta
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 26, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments